BR112016017402A2 - fusões anti-pcsk9~glp-1 e métodos para uso - Google Patents

fusões anti-pcsk9~glp-1 e métodos para uso

Info

Publication number
BR112016017402A2
BR112016017402A2 BR112016017402A BR112016017402A BR112016017402A2 BR 112016017402 A2 BR112016017402 A2 BR 112016017402A2 BR 112016017402 A BR112016017402 A BR 112016017402A BR 112016017402 A BR112016017402 A BR 112016017402A BR 112016017402 A2 BR112016017402 A2 BR 112016017402A2
Authority
BR
Brazil
Prior art keywords
pcsk9
glp
fusions
methods
relates
Prior art date
Application number
BR112016017402A
Other languages
English (en)
Inventor
Buchanan Andrew
CELESTE Anthony
Rondinone Cristina
Fairman David
Seaman Jonathan
Grimsby Joseph
Chodorge Matthieu
Ravn Peter
Original Assignee
Medimmune Ltd
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd, Medimmune Llc filed Critical Medimmune Ltd
Publication of BR112016017402A2 publication Critical patent/BR112016017402A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

a presente invenção refere-se a fusões anti-pcsk9~glp-1 e métodos para uso.
BR112016017402A 2014-02-21 2015-02-20 fusões anti-pcsk9~glp-1 e métodos para uso BR112016017402A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461943300P 2014-02-21 2014-02-21
US201461944550P 2014-02-25 2014-02-25
PCT/US2015/016911 WO2015127273A1 (en) 2014-02-21 2015-02-20 Anti-pcsk9~glp-1 fusions and methods for use

Publications (1)

Publication Number Publication Date
BR112016017402A2 true BR112016017402A2 (pt) 2017-10-17

Family

ID=53879052

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016017402A BR112016017402A2 (pt) 2014-02-21 2015-02-20 fusões anti-pcsk9~glp-1 e métodos para uso

Country Status (12)

Country Link
US (1) US10077319B2 (pt)
EP (1) EP3107937A4 (pt)
JP (1) JP2017512457A (pt)
KR (1) KR20160124787A (pt)
CN (1) CN106232627A (pt)
BR (1) BR112016017402A2 (pt)
CA (1) CA2935285A1 (pt)
MX (1) MX2016009858A (pt)
RU (1) RU2016137264A (pt)
SG (1) SG11201606684YA (pt)
TW (1) TW201538523A (pt)
WO (1) WO2015127273A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10058630B2 (en) * 2012-10-22 2018-08-28 Concievalve, Llc Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis
JP2017525680A (ja) * 2014-07-14 2017-09-07 アムジェン インコーポレイテッド 結晶性抗体製剤
IL250583B (en) 2014-08-19 2022-07-01 Merck Sharp & Dohme Anti-tigit antibodies
US10766957B2 (en) 2015-08-14 2020-09-08 Merck Sharp & Dohme Corp Anti-TIGIT antibodies
KR102417487B1 (ko) 2016-01-13 2022-07-06 노보 노르디스크 에이/에스 지방산 치환기를 가진 egf(a) 유사체
ES2835033T3 (es) 2016-03-03 2021-06-21 Novo Nordisk As Derivados de GLP-1 y sus usos
US10633434B2 (en) 2016-06-14 2020-04-28 Regeneron Pharmaceuticals, Inc. Anti-C5 antibodies
WO2018026742A1 (en) * 2016-08-01 2018-02-08 Askgene Pharma Inc. Novel antibody-albumin-drug conjugates (aadc) and methods for using them
CA3068956A1 (en) 2017-07-19 2019-01-24 Novo Nordisk A/S Bifunctional compounds
AU2018383751A1 (en) 2017-12-13 2020-06-25 Regeneron Pharmaceuticals, Inc. Anti-C5 antibody combinations and uses thereof
TW202028229A (zh) 2018-10-05 2020-08-01 丹麥商諾佛 儂迪克股份有限公司 包含胰島素肽及ｅｇｆ（ａ）肽之雙功能化合物
US20220323548A1 (en) * 2019-08-13 2022-10-13 Anygen Co., Ltd. Exenatide analog and use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2505207B1 (en) * 2005-01-14 2015-04-22 Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. Modified exendins and uses thereof
WO2008085982A2 (en) * 2007-01-08 2008-07-17 The Trustees Of The University Of Pennsylvania Methods and compositions for treating hypoglycemic disorders
EP2185178B1 (en) * 2007-08-03 2017-08-23 Eli Lilly And Company Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
MX2011010151A (es) * 2009-03-27 2011-12-14 Glaxo Group Ltd Fusiones y conjugados de farmaco.
CN101665799A (zh) * 2009-06-29 2010-03-10 华东师范大学 一种Exendin-4衍生物的重组制备方法和应用
CN101993485B (zh) 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
WO2011111007A2 (en) * 2010-03-11 2011-09-15 Rinat Neuroscience Corporation ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
EP2576616A4 (en) 2010-05-27 2014-05-21 Merck Sharp & Dohme PROCESS FOR PREPARING ANTIBODIES WITH IMPROVED PROPERTIES
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US9255154B2 (en) * 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
TWI513705B (zh) * 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) * 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物

Also Published As

Publication number Publication date
EP3107937A4 (en) 2017-11-15
TW201538523A (zh) 2015-10-16
US20160369010A1 (en) 2016-12-22
MX2016009858A (es) 2017-01-26
JP2017512457A (ja) 2017-05-25
CN106232627A (zh) 2016-12-14
EP3107937A1 (en) 2016-12-28
KR20160124787A (ko) 2016-10-28
US10077319B2 (en) 2018-09-18
RU2016137264A (ru) 2018-03-26
WO2015127273A1 (en) 2015-08-27
CA2935285A1 (en) 2015-08-27
RU2016137264A3 (pt) 2018-11-30
SG11201606684YA (en) 2016-09-29

Similar Documents

Publication Publication Date Title
BR112016017402A2 (pt) fusões anti-pcsk9~glp-1 e métodos para uso
CL2015002562A1 (es) Anticuerpos e inmunoconjugados anti-b7-h4
TWD170094S (zh) 錶
CL2014003042S1 (es) Carcasa para autoinyector.
NI201700054A (es) Síntesis de copanlisib y su sal diclorhidrato
BR112017000456A2 (pt) composições antivirais tópicas e métodos de uso das mesmas
AR095048A1 (es) Proceso electroquímico para el acoplamiento de fenol a anilina
TWD174678S (zh) 手錶
TWD173500S (zh) 可攜式列印機
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
UY36396A (es) Síntesis de copanlisib y su sal diclorhidrato
AU357215S (en) Positioning element for construction toy
TWD171659S (zh) 錶殼
BR112015023440A2 (pt) torradeira para tortilha aperfeiçoada
DE112015003003A5 (de) Kraftstoffleitung
FI20145854A (fi) Polttoainekoostumus
ES1078864Y (es) Carpeta-silla transportable.
UA104459U (uk) Застосування лактопротеїну з сорбітолом як цитопротектора аденогіпофіза при опіковій хворобі
TN2014000468A1 (fr) اختراع الة للف شباك مراكب الصيد البحري و تسهيل تحويلها من المركب الى رصيف الميناء ثم ارجاعها للمركب بعد القيام بعملية ترقيعها
TN2014000388A1 (fr) منظومة فيزيائية متجانسة كهربائية ميكانيكية مغناطيسية لتوليد الطاقة الكهربائية الحرة الايكولوجية المضاعفة
TN2014000355A1 (fr) طريقة مبتكرة لتوفير الاضاءة العامة و المنزلية
TN2014000354A1 (fr) جهاز مبتكر لتلقيح النخيل
DOS2014000289S (es) Mesas
ES1127755Y (es) Sofa con respaldo oscilante
TN2014000377A1 (fr) طائرة كهربائية كاتمة للصوت

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B25A Requested transfer of rights approved

Owner name: MEDIMMUNE LIMITED. (GB)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]